Jump to content

Substance P

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by 82.47.136.229 (talk) at 21:52, 26 November 2011 (changed date from 2011 to that given by article referenced.). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

tachykinin, precursor 1
Spacefilling model of substance P
Identifiers
SymbolTAC1
Alt. symbolsTAC2, NKNA
NCBI gene6863
HGNC11517
OMIM162320
RefSeqNM_003182
UniProtP20366
Other data
LocusChr. 7 q21-q22
Search for
StructuresSwiss-model
DomainsInterPro
Substance P
Identifiers
ChEMBL
ChemSpider
ECHA InfoCard 100.046.845 Edit this at Wikidata
MeSH Substance+P
  • InChI=1S/C63H98N18O13S/c1-37(2)33-45(57(89)74-41(53(68)85)27-32-95-3)73-52(84)36-72-54(86)46(34-38-15-6-4-7-16-38)78-58(90)47(35-39-17-8-5-9-18-39)79-56(88)42(23-25-50(66)82)75-55(87)43(24-26-51(67)83)76-59(91)49-22-14-31-81(49)62(94)44(20-10-11-28-64)77-60(92)48-21-13-30-80(48)61(93)40(65)19-12-29-71-63(69)70/h4-9,15-18,37,40-49H,10-14,19-36,64-65H2,1-3H3,(H2,66,82)(H2,67,83)(H2,68,85)(H,72,86)(H,73,84)(H,74,89)(H,75,87)(H,76,91)(H,77,92)(H,78,90)(H,79,88)(H4,69,70,71)/t40-,41-,42-,43-,44-,45-,46-,47-,48-,49-/m0/s1 checkY
    Key: ADNPLDHMAVUMIW-CUZNLEPHSA-N checkY
  • InChI=1/C63H98N18O13S/c1-37(2)33-45(57(89)74-41(53(68)85)27-32-95-3)73-52(84)36-72-54(86)46(34-38-15-6-4-7-16-38)78-58(90)47(35-39-17-8-5-9-18-39)79-56(88)42(23-25-50(66)82)75-55(87)43(24-26-51(67)83)76-59(91)49-22-14-31-81(49)62(94)44(20-10-11-28-64)77-60(92)48-21-13-30-80(48)61(93)40(65)19-12-29-71-63(69)70/h4-9,15-18,37,40-49H,10-14,19-36,64-65H2,1-3H3,(H2,66,82)(H2,67,83)(H2,68,85)(H,72,86)(H,73,84)(H,74,89)(H,75,87)(H,76,91)(H,77,92)(H,78,90)(H,79,88)(H4,69,70,71)/t40-,41-,42-,43-,44-,45-,46-,47-,48-,49-/m0/s1
    Key: ADNPLDHMAVUMIW-CUZNLEPHBU
Properties
C63H98N18O13S
Molar mass 1347.63 g/mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
checkY verify (what is checkY☒N ?)

In the field of neuroscience, substance P (SP) is a neuropeptide: an undecapeptide that functions as a neurotransmitter and as a neuromodulator.[1][2] It belongs to the tachykinin neuropeptide family. Substance P and its closely related neuropeptide neurokinin A (NKA) are produced from a polyprotein precursor after differential splicing of the preprotachykinin A gene. The deduced amino acid sequence of substance P is as follows[citation needed]:

Substance P is released from the terminals of specific sensory nerves, it is found in the brain and spinal cord, and is associated with inflammatory processes and pain.

Discovery

Substance P was originally discovered in 1931 by Ulf von Euler and John H. Gaddum as a tissue extract that caused intestinal contraction in vitro.[3] Its tissue distribution and biologic actions were further investigated over the following decades.[1] In 1983, NKA (previously known as substance K or neuromedin L) was isolated from porcine spinal cord and was also found to stimulate intestinal contraction.[4]

Receptor

The endogenous receptor for substance P is neurokinin 1 receptor (NK1-receptor, NK1R).[5] It belongs to the tachykinin receptor sub-family of GPCRs.[6] Other neurokinin subtypes and neurokinin receptors that interact with SP have also been reported. Amino acid residues that are responsible for the binding of SP and its antagonists are present in the extracellular loops and transmembrane regions of NK-1. Binding of SP to NK-1 results in internalization by the clathrin-dependent mechanism to the acidified endosomes where the complex disassociates. SP is subsequently degraded and NK-1 is re-expressed on the cell surface.[7] Substance P and the NK1 receptor are widely distributed in the brain and are specifically found in brain regions that regulate emotion (hypothalamus, amygdala, and the periaqueductal gray).[8] They are also found in close association with serotonin (5-HT) and neurons containing norepinephrine that are targeted by the currently used antidepressant drugs.[9] The SP receptor promoter contains regions that are sensitive to cAMP, AP-1, AP-4, CEBPB[10] and epidermal growth factor. Because these regions are related to complexed signal transduction pathways mediated by cytokines, it has been proposed that cytokines and neurotropic factors can induce NK-1. SP can also induce the cytokines that are capable of inducing NK-1 transcription factors.[11]

Function

Substance P is an important element in pain perception. The sensory function of substance P is thought to be related to the transmission of pain information into the central nervous system. Substance P coexists with the excitatory neurotransmitter glutamate in primary afferents that respond to painful stimulation.[12] Substance P has been associated with the regulation of mood disorders, anxiety, stress,[13] reinforcement,[14] neurogenesis,[15] respiratory rhythm,[16] neurotoxicity, nausea/emesis,[17] pain and nociception.[18] Substance P and other sensory neuropeptides can be released from the peripheral terminals of sensory nerve fibers in the skin, muscle and joints. It is proposed that this release is involved in neurogenic inflammation, which is a local inflammatory response to certain types of infection or injury.[19] The regulatory function of SP also involves the regulation of its high-affinity receptor, NK-1. Substance P receptor antagonists may have important therapeutic applications in the treatment of a variety of stress-related illnesses, in addition to their potential as analgesics.

Vomiting

The vomiting center in the medulla contains high concentrations of substance P and its receptor, in addition to other neurotransmitters such as choline, histamine, dopamine, serotonin, and opioids. Their activation stimulates the vomiting reflex. Different emetic pathways exist, and substance P/NK1R appears to be within the final common pathway to regulate vomiting.[20] Substance P antagonist (SPA) aprepitant is available in the market in the treatment of chemotherapy-induced nausea/emesis.

Pain

Substance P is involved in nociception, transmitting information about tissue damage from peripheral receptors to the central nervous system to be converted to the sensation of pain. It has been theorized that it plays a part in fibromyalgia. Capsaicin has been shown to reduce the levels of substance P, it is presumed, by reducing the number of C-fibre nerves or causing these nerves to be more tolerant. Thus, Capsaicin is clinically used as an analgesic and an inflammatory agent to reduce pain associated with arthritis and many types of neuralgia. A role of substance P and NKA in nociception is suggested by the reduction in response thresholds to noxious stimuli by central administration of K2 and K3 agonists. Based on recent studies, it was proposed that NK1, and possibly the NK2 receptor antagonists, could be developed as analgesic drugs. It has been studied that the mice carrying a disruption of the gene encoding SP/NKA show severely reduced nociceptive pain responses when the stimuli are moderate to intense. Pain behaviors induced by mechanical, thermal, and chemical stimulation of somatic and visceral tissues were reduced in the mutant mice lacking SP/NKA. However, it has been proposed that the importance of SP and NKA in animal's pain response apply only to a certain 'window' of pain intensities, and, when the intensity of the pain stimuli is further increased, the responses of the knockout mice is not severely different from the wild-type mice.[12]

Substance P increases glutamate activity (NMDA) in central nervous system, and it is associated with the development of brain edema and functional deficits after traumatic brain injury.[21]

Cell growth

Substance P has been known to stimulate cell growth in culture,[22] and it was shown that substance P could promote wound healing of non-healing ulcers in humans.[23]

Diabetes

Substance P injected into pancreatic nerves has been shown to reverse diabetes in mice[24][25] but effects to insulin secretion seems to be species dependent. In humans, substance P seems to decrease insulin release and cause fluctuations in blood sugar levels.[26]

Vasodilation

Substance P also has effects as a potent vasodilator. Substance P-induced vasodilatation is dependent on nitric oxide release.[27] Substance P is involved in the axon reflex-mediated vasodilatation to local heating and wheal and flare reaction. It has been shown that vasodilatation to substance P is dependent on the NK1 receptor located on the endothelium. In contrast to other neuropeptides studied in human skin, substance P-induced vasodilatation has been found to decline during continuous infusion. This possibly suggest an internalization of neurokinin-1 (NK1).[28] As is typical with many vasodilators, it also has bronchoconstrictive properties, administered through the non-adrenergic, non-cholinergic nervous system (branch of the vagal system).

Clinical significance

Eczema

High levels of BDNF and substance P have been found associated with increased itching in eczema.[29][30]

Gastrointestinal infection

Entamoeba histolytica is a single-celled parasitic protozoan that infects the lower gastrointestinal tract of humans. The symptoms of infection are diarrhea, constipation, and abdominal pain.[31][32] This protozoan was found to secrete serotonin[33] as well as substance P and neurotensin.[34]

Denervation supersensitivity

When the innervation to substance P nerve terminals is lost, post-synaptic cells compensate for the loss of adequate neurotransmitter by increasing the expression of post-synaptic receptors. This, ultimately, leads to a condition known as Denervation Supersensitivity as the post-synaptic nerves will become hypersensitive to any invasion of substance P into the synaptic cleft.

Deficiency

Naked mole rats lack cutaneous C fibers reactive to substance P (SP) and many small neurons that are normally SP-positive. Thus, these animals are insensitive to pain when painful stimuli are administered to the skin.[35][36] New studies have shown that when the function of SP is genetically disrupted in mice, the animals demonstrated reduced responses to painful stimuli. Moreover, the response to capsaicin was absent or severely reduced in knockout mice.[12]

References

  1. ^ a b Harrison S, Geppetti P (2001). "Substance p". The International Journal of Biochemistry & Cell Biology. 33 (6): 555–76. doi:10.1016/S1357-2725(01)00031-0. PMID 11378438. {{cite journal}}: Unknown parameter |month= ignored (help)
  2. ^ Datar P, Srivastava S, Coutinho E, Govil G (2004). "Substance P: structure, function, and therapeutics". Current Topics in Medicinal Chemistry. 4 (1): 75–103. doi:10.2174/1568026043451636. PMID 14754378.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  3. ^ V Euler US, Gaddum JH (1931). "An unidentified depressor substance in certain tissue extracts". The Journal of Physiology. 72 (1): 74–87. PMC 1403098. PMID 16994201. {{cite journal}}: Unknown parameter |month= ignored (help)
  4. ^ Panula P, Hadjiconstantinou M, Yang HY, Costa E (1983). "Immunohistochemical localization of bombesin/gastrin-releasing peptide and substance P in primary sensory neurons". Journal of Neuroscience. 3 (10): 2021–9. PMID 6194276. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  5. ^ Gerard NP, Garraway LA, Eddy RL Jr, Shows TB, Iijima H, Paquet JL, Gerard C (1991). "Human substance P receptor (NK-1): organization of the gene, chromosome localization, and functional expression of cDNA clones". Biochemistry. 30 (44): 10640–6. doi:10.1021/bi00108a006. PMID 1657150. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  6. ^ Maggi CA (1995). "The mammalian tachykinin receptors". Gen. Pharmacol. 26 (5): 911–44. doi:10.1016/0306-3623(94)00292-U. PMID 7557266.
  7. ^ Grady EF, Garland AM, Gamp PD, Lovett M, Payan DG, Bunnett NW (1995). "Delineation of the endocytic pathway of substance P and its seven-transmembrane domain NK1 receptor". Molecular Biology of the Cell. 6 (5): 509–24. PMC 301212. PMID 7545030. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  8. ^ Yip J, Chahl LA (2001). "Localization of NK1 and NK3 receptors in guinea-pig brain". Regulatory peptides. 98 (1–2): 55–62. doi:10.1016/S0167-0115(00)00228-7. PMID 11179779. {{cite journal}}: Unknown parameter |month= ignored (help)
  9. ^ Gobbi G, Cassano T, Radja F, Morgese MG, Cuomo V, Santarelli L, Hen R, Blier P (2007). "Neurokinin 1 receptor antagonism requires norepinephrine to increase serotonin function". European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 17 (5): 328–38. doi:10.1016/j.euroneuro.2006.07.004. PMID 16950604. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  10. ^ Kovács KA, Steinmann M, Magistretti PJ, Halfon O, Cardinaux JR (2006). "C/EBPbeta couples dopamine signalling to substance P precursor gene expression in striatal neurones". Journal of Neurochemistry. 98 (5): 1390–9. doi:10.1111/j.1471-4159.2006.03957.x. PMID 16771829. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  11. ^ Rameshwar P (1997). "Substance P: a regulatory neuropeptide for hematopoiesis and immune functions". Clinical Immunology and Immunopathology. 85 (2): 129–33. doi:10.1006/clin.1997.4446. PMID 9344694. {{cite journal}}: Unknown parameter |month= ignored (help)
  12. ^ a b c De Felipe C, Herrero JF, O'Brien JA, Palmer JA, Doyle CA, Smith AJ, Laird JM, Belmonte C, Cervero F, Hunt SP (1998). "Altered nociception, analgesia and aggression in mice lacking the receptor for substance P". Nature. 392 (6674): 394–7. doi:10.1038/32904. PMID 9537323. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  13. ^ Ebner K, Singewald N (2006). "The role of substance P in stress and anxiety responses". Amino acids. 31 (3): 251–72. doi:10.1007/s00726-006-0335-9. PMID 16820980. {{cite journal}}: Unknown parameter |month= ignored (help)
  14. ^ Huston JP, Hasenöhrl RU, Boix F, Gerhardt P, Schwarting RK (1993). "Sequence-specific effects of neurokinin substance P on memory, reinforcement, and brain dopamine activity". Psychopharmacology. 112 (2–3): 147–62. doi:10.1007/BF02244906. PMID 7532865.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  15. ^ Park SW, Yan YP, Satriotomo I, Vemuganti R, Dempsey RJ (2007). "Substance P is a promoter of adult neural progenitor cell proliferation under normal and ischemic conditions". Journal of neurosurgery. 107 (3): 593–9. doi:10.3171/JNS-07/09/0593. PMID 17886560. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  16. ^ Bonham AC (1995). "Neurotransmitters in the CNS control of breathing". Respiration physiology. 101 (3): 219–30. doi:10.1016/0034-5687(95)00045-F. PMID 8606995. {{cite journal}}: Unknown parameter |month= ignored (help)
  17. ^ Hesketh PJ (2001). "Potential role of the NK1 receptor antagonists in chemotherapy-induced nausea and vomiting". Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 9 (5): 350–4. doi:10.1007/s005200000199. PMID 11497388. {{cite journal}}: Unknown parameter |month= ignored (help)
  18. ^ Zubrzycka M, Janecka A (2000). "Substance P: transmitter of nociception (Minireview)". Endocrine regulations. 34 (4): 195–201. PMID 11137976. {{cite journal}}: Unknown parameter |month= ignored (help)
  19. ^ Donkin JJ, Turner RJ, Hassan I, Vink R (2007). "Substance P in traumatic brain injury". Progress in brain research. 161: 97–109. doi:10.1016/S0079-6123(06)61007-8. PMID 17618972.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  20. ^ Hornby PJ (2001). "Central neurocircuitry associated with emesis". The American Journal of Medicine. 111. Suppl 8A (8): 106S–112S. doi:10.1016/S0002-9343(01)00849-X. PMID 11749934. {{cite journal}}: Unknown parameter |month= ignored (help)
  21. ^ Donkin JJ, Nimmo AJ, Cernak I, Blumbergs PC, Vink R (2009). "Substance P is associated with the development of brain edema and functional deficits after traumatic brain injury". J Cereb Blood Flow Metab. 29 (8): 1388–98. doi:10.1038/jcbfm.2009.63. PMID 19436311. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  22. ^ Reid TW, Murphy CJ, Iwahashi CK, Foster BA, Mannis MJ (1993). "Stimulation of epithelial cell growth by the neuropeptide substance P". Journal of Cellular Biochemistry. 52 (4): 476–85. doi:10.1002/jcb.240520411. PMID 7693729. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  23. ^ Brown SM, Lamberts DW, Reid TW, Nishida T, Murphy CJ (1997). "Neurotrophic and anhidrotic keratopathy treated with substance P and insulinlike growth factor 1". Archives of Ophthalmology. 115 (7): 926–7. PMID 9230840. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  24. ^ Motluk A, Geddes L (2005-12-15). "Breakthrough sheds light on cause of diabetes". Health. New Scientist. Retrieved 2008-11-01. {{cite web}}: Cite has empty unknown parameter: |coauthors= (help)
  25. ^ Tsui H, Razavi R, Chan Y, Yantha J, Dosch HM (2007). "'Sensing' autoimmunity in type 1 diabetes". Trends in Molecular Medicine. 13 (10): 405–13. doi:10.1016/j.molmed.2007.07.006. PMID 17900987. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  26. ^ Brown, M and Vale, W (1976). "Effects of neurotensin and substance P on plasma insulin, glucagon and glucose levels". Endocrinology. 98 (3): 819–822. doi:10.1210/endo-98-3-819. PMID 1261503.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  27. ^ Bossaller C, Reither K, Hehlert-Friedrich C, Auch-Schwelk W, Graf K, Gräfe M, Fleck E (1992). "In vivo measurement of endothelium-dependent vasodilation with substance P in man". Herz. 17 (5): 284–90. PMID 1282120. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  28. ^ Wong BJ, Tublitz NJ, Minson CT (2005). "Neurokinin-1 receptor desensitization to consecutive microdialysis infusions of substance P in human skin". The Journal of Physiology. 568 (Pt 3): 1047–56. doi:10.1113/jphysiol.2005.095372. PMC 1464169. PMID 16123103. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  29. ^ Hon KL, Lam MC, Wong KY, Leung TF, Ng PC (2007). "Pathophysiology of nocturnal scratching in childhood atopic dermatitis: the role of brain-derived neurotrophic factor and substance P". The British Journal of Dermatology. 157 (5): 922–5. doi:10.1111/j.1365-2133.2007.08149.x. PMID 17725670. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  30. ^ Steinitz H (1979). "[Chronic recurrent intestinal amebiasis in Israel (author's transl)]". Leber, Magen, Darm (in German). 9 (4): 175–9. PMID 491812.
  31. ^ Stark D, van Hal S, Marriott D, Ellis J, Harkness J (2007). "Irritable bowel syndrome: a review on the role of intestinal protozoa and the importance of their detection and diagnosis". Int. J. Parasitol. 37 (1): 11–20. doi:10.1016/j.ijpara.2006.09.009. PMID 17070814.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  32. ^ McGowan K, Kane A, Asarkof N; et al. (1983). "Entamoeba histolytica causes intestinal secretion: role of serotonin". Science. 221 (4612): 762–4. doi:10.1126/science.6308760. PMID 6308760. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  33. ^ McGowan K, Guerina V, Wicks J, Donowitz M (1985). "Secretory hormones of Entamoeba histolytica". Ciba Found. Symp. 112: 139–54. PMID 2861068.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  34. ^ Park TJ, Comer C, Carol A, Lu Y, Hong HS, Rice FL (2003). "Somatosensory organization and behavior in naked mole-rats: II. Peripheral structures, innervation, and selective lack of neuropeptides associated with thermoregulation and pain". J Comp Neurol. 465 (1): 104–20. doi:10.1002/cne.10824. PMID 12926019.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  35. ^ Pepling, Rachel Sheremeta (2004-01-07). "Ugly Ducklings". Chemical & Engineering News. Retrieved 2007-08-14. {{cite web}}: Italic or bold markup not allowed in: |publisher= (help)

Template:Neuropeptidergics

Retrieved from "https://en.wikipedia.org/w/index.php?title=Substance_P&oldid=462632140"